Compare UUU & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUU | BIAF |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.2M |
| IPO Year | 2025 | 2022 |
| Metric | UUU | BIAF |
|---|---|---|
| Price | $5.21 | $4.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.0K | ★ 3.1M |
| Earning Date | 08-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,847,163.00 | ★ $7,900,000.00 |
| Revenue This Year | N/A | $18.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $3.02 | $0.33 |
| 52 Week High | $7.82 | $20.35 |
| Indicator | UUU | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 40.59 |
| Support Level | $4.61 | $4.71 |
| Resistance Level | $5.41 | $5.93 |
| Average True Range (ATR) | 0.35 | 0.82 |
| MACD | 0.01 | -0.44 |
| Stochastic Oscillator | 61.36 | 1.28 |
Universal Safety Products Inc designs and markets a variety of popularly priced safety products which, consisted mainly of smoke alarms, carbon monoxide alarms and related products. Its products require minimal installation and are designed for easy installation by the consumer without professional assistance and are sold through retail stores. It also market products to the electrical distribution trade. The electrical distribution trade includes electrical and lighting distributors as well as manufactured housing companies. Products it sell usually require professional installation. Its products are 2-in-1 Smoke & Fire Alarms, 3-in-1 Combo Alarms, and CO Alarms.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.